Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
  • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/15—Depsipeptides; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to the treatment of viral infections from the Orthomyxoviridae family or wherein the virus is West Nile virus.
• Treating viral infections is not only important for reducing disease severity, but also for preventing disease and minimising viral transmission.
• a number of viruses cause life-long infections that can be effectively managed or cured by treatment. Almost all viruses are capable of causing complications in vulnerable patients, such as viremia, pneumonia and sepsis, but certain viruses can cause severe infections that if left untreated in any individual can result in organ damage, organ failure, and even death. These symptoms arise due to the virus itself but can also be caused by an excessive immune response.
• Some viruses are latent and do not cause symptomatic illness immediately following infection. While latent viruses can lead to the inadvertent spread of the virus to other individuals, they can also become reactivated several years after the initial infection, causing severe symptoms that are often fatal and could have been avoided with earlier treatment.
• WNV West Nile Virus
• Influenza viruses cause a common illness known as ‘flu’ and are particularly prevalent among the population in the winter months. Most individuals infected with influenza develop a mild respiratory illness, but disease burden increases with age and individuals with weakened immune systems are at risk of developing more severe illness. The mortality rate of influenza is reported as between 0.1 and 0.5% in the US, but the mortality rate varies depending on the particular influenza strain and country. The World Health Organisation estimated that seasonal influenza epidemics cause 3-5 million cases of severe illness and 291,000-646,000 deaths globally each year. Due to the ability of influenza viruses to undergo genetic shift, specific influenza strains can have significantly higher mortality rates and are capable of causing pandemics. Notably, four influenza pandemics have occurred since 1900 (H1N1 Spanish flu, H2N2 Asian flu, H3N2 Hong Kong flu, the H1N1 swine flu).
• the present invention is directed to a compound of general formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is selected from O and NH;
• Y is selected from CO and -COCH(CH3)CO-; each n and p is independently selected from 0 and 1, and q is selected from 0, 1 and 2; each Rl, R3, R5, R9, Rll, and R15 is independently selected from hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, and substituted or unsubstituted C2-C6 alkynyl;
• R2 is selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, and substituted or unsubstituted C2-C6 alkynyl; each R4, R8, RIO, R12, and R16 is independently selected from hydrogen and substituted or unsubstituted C1-C6 alkyl; each R7 and R13 is independently selected from hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, and substituted or unsubstituted C2-C6 alkynyl; each R6 and R14 is independently selected from hydrogen and substituted or unsubstituted Cl- C6 alkyl; or R6 and R7 and/or R13 and R14 together with the corresponding N atom and C atom to which they are attached may form a substituted or unsubstituted heterocyclic group
• the compound of general formula I is DidemninB, or a pharmaceutically acceptable salt or stereoisomer thereof.
• the present invention is also directed to a pharmaceutical composition
• a pharmaceutical composition comprising a compound as defined herein, and a pharmaceutically acceptable carrier, for use according to the present invention.
• the present invention is directed to the use of a compound as defined herein, in the manufacture of a medicament for the treatment of a viral infection, wherein the virus is selected from the Orthomyxoviridae family or wherein the virus is West Nile virus.
• the present invention is directed to a method for treating a viral infection in any mammal, preferably a human, wherein the method comprises administering to an individual in need thereof a therapeutically effective amount of a compound as defined herein, and wherein the virus is selected from the Orthomyxoviridae family or wherein the virus is West Nile virus.
• kits comprising the compound as defined herein, together with instructions for treating a viral infection, wherein the virus is selected from the Orthomyxoviridae family or wherein the virus is West Nile virus.
• the Orthomyxoviridae virus is selected from Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogotovirus, Quaranjavirus, and Isavirus.
• the Orthomyxoviridae virus is Influenza A, preferably selected from H1N1, H1N2 and H3N2.
• the Orthomyxoviridae virus is influenza B, preferably selected from the Yamagata or Victoria lineages.
• the West Nile virus is selected from lineage 1, 2, 3, 4, 5, 6, 7 or 8.
• the virus is lineage 1 or 2 (WNV-1 or WNV-2).
• the west nile virus is West Nile-NY99.
• R3 and R4 may be independently selected from hydrogen and substituted or unsubstituted CYO, alkyl.
• R3 may be isopropyl and R4 may be hydrogen.
• R3 and R4 may be methyl (this compound is also designated a compound of general formula II).
• R 11 may be selected from hydrogen and substituted or unsubstituted CVO, alkyl.
• Rn may be methyl or isobutyl.
• Ri, R 5 , R 9 , and R 15 may be independently selected from hydrogen and substituted or unsubstituted C I -C , alkyl.
• Ri may be selected from sec-butyl and isopropyl
• R5 may be isobutyl
• R9 may be p- methoxybenzyl
• R15 may be selected from methyl and benzyl.
• ( may be independently selected from hydrogen and substituted or unsubstituted CVO, alkyl.
• Rs, Rio and R12 may be methyl, and Ri 6 may be hydrogen.
• R 6 and Ri4 may be independently selected from hydrogen and substituted or unsubstituted C 1 -G, alkyl.
• R6 may be selected from hydrogen and methyl, and R « may be hydrogen.
• R7 and Ri3 may be independently selected from hydrogen and substituted or unsubstituted C 1 -G, alkyl.
• R7 may be methyl and R13 may be selected from hydrogen, methyl, isopropyl, isobutyl, and 3-amino-3-oxopropyl.
• Re and R7 and/or R13 and R « together with the corresponding N atom and C atom to which they are attached may form a substituted or unsubstituted pyrrolidine group.
• R2 may be selected from hydrogen, substituted or unsubstituted C1-C6 alkyl, and COR a , and wherein R a may be a substituted or unsubstituted C1-C6 alkyl. R2 may be hydrogen.
• Rn may be selected from hydrogen, COObenzyl, CObenzo[b]thiophen-2-yl, S0 2 (p-methylphenyl), COCOCH3 and COOC(CH 3 ) 3 .
• X may be NH.
• X may be O.
• Y may be CO.
• Y may be -COCH(CH3)CO-.
• the compound may be PLD, or pharmaceutically acceptable salts or stereoisomers thereof.
• the compound may be PLD.
• the compound may be didemninB, or pharmaceutically acceptable salts or stereoisomers thereof.
• the compound may be didemninB.
• the viral infection may be a mild infection; and/or moderate infection; and/or severe infection.
• the use may include use in the treatment of a patient with signs and symptoms of the viral infection for up to 4 weeks; and/or from 4 weeks to 12 weeks; and/or for more than 12 weeks.
• the use may include use in the prophylaxis, reduction or treatment of persistent, viral symptoms.
• the use may reduce the infectivity of infected patients; including wherein the patient is asymptomatic or not very symptomatic yet has a high viral load.
• the use may reduce the occurrence of supercontagators (asymptomatic or not very symptomatic patients with high viral loads (e.g. TC ⁇ 25)).
• the present invention achieves a rapid and significant reduction in the viral burden. Reducing the viral burden may reduce the infectiveness of patients. This is particulary beneficial with patients who are asymptomatic or not very symptomatic yet have a high viral loads (e.g. TC ⁇ 25). Such patients may be supercontagators or superspreaders. Administration of compounds according to the present invention upon detection of infection can reduce the viral burden and therefore reduce the infectiveness of the patient.
• the treatment may result in a reduction of viral load. This may be expressed as a replication cycle threshold (Ct) value greater than 30 (Ct> 30), on day 6 after the administration.
• the treatment may reduce viral load from baseline. This may be expressed as a reduction in the percentage of patients requiring hospitalisation following administration. This may be expressed as a reduction in the percentage of patients requiring invasive mechanical ventilation and / or admission to the ICU following administration. This may be expressed as a reduction of patients who develop sequelae related to persistent disease. This may be expressed as an increase in the percentage of patients with normalization of analytical parameters chosen as poor prognosis criteria (including, for example, lymphopenia, LDH, D-dimer or PCR).
• This may be expressed as an increase in the percentage of patients with normalization of clinical criteria (disappearance of symptoms), including, for example: headache, fever, cough, fatigue, dyspnea (shortness of breath), arthromyalgia or diarrhoea.
• the compound may be administered in combination with a corticosteroid, preferably dexamethasone.
• a corticosteroid preferably dexamethasone.
• the compound and corticosteroid may be administered concurrently, separately or sequentially.
• the compound may be administered according to a regimen of a once daily dose for 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day; preferably 2-5 days, 3-5 days, or 3, 4 or 5 days; most preferably 3 days or 5 days; most preferably 3 days.
• the compound may be administered at a dose of 5mg a day or less, 4.5mg a day or less, 4mg a day or less, 3.5mg a day or less, 3mg a day or less, 2.5mg a day or less or 2mg a day or less; 0.5 mg/day, 1 mg/day, 1.5 mg/day, 2 mg/day, 2.5 mg/day, 3 mg/day, 3.5 mg/day, 4 mg/day, 4.5 mg/day, or 5mg/day; preferably 1 mg/day, 1.5 mg/day, 2 mg/day or 2.5 mg/day; preferably 1.5- 2.5 mg/day; further preferably 1.5 mg/day, 2 mg/day or 2.5 mg/day.
• the compound may be administered at a total dose of 1-50 mg, 1-40 mg, 1-30 mg, 1-20 mg, 1- 15 mg, 3-15 mg, 3-12 mg, 4-12 mg, 4-10 mg, or 4.5-10 mg; 4mg, 4.5mg, 5mg, 5.5mg, 6mg, 6.5mg, 7mg, 7.5mg, 8mg, 8.5mg, 9mg, 9.5mg or lOmg; preferably 4.5mg, 5mg, 6mg, 7.5mg, 8mg, 9mg or lOmg; more preferably 4.5-7.5 mg/day.
• the total dose may be split over 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days, preferably 3 days or 5 days; most preferably 3 days.
• the compound may be administered at a once daily dose for 3 days at a dose of 1.5-2.5mg/day.
• the dose may be 1.5mg/day.
• the dose may be 2.5mg/day.
• the compound may be PLD administered as a 1.5-hour infusion, once a day for 3 consecutive days.
• 1.5 mg of PLD may be administered as a 1.5-hour infusion, once a day for 3 consecutive days.
• 2 mg of PLD may be administered as a 1.5-hour infusion, once a day for 3 consecutive days.
• 2.5 mg of PLD may be administered as a 1.5-hour infusion, once a day for 3 consecutive days.
• 1 mg of PLD may be administered as a 1.5-hour infusion, once a day for 5 consecutive days.
• 2 mg of PLD may be administered as a 1.5-hour infusion, once a day for 5 consecutive days.
• the regimen may be a single dose (1 day).
• the compound may be administered as a single dose of 1-10 mg, 4-10 mg, 4.5-10 mg; 4mg, 4.5mg, 5mg, 5.5mg, 6mg, 6.5mg, 7mg, 7.5mg, 8mg, 8.5mg, 9mg, 9.5mg or lOmg; preferably 4.5mg, 5mg, 6mg, 7.5mg, 8mg, 9mg or lOmg; more preferably 5-9 mg, 6.5-8.5 mg, 7-8 mg or 7.5 mg.
• the compound may be PLD administered as a single dose 1.5-hour infusion.
• the single dose regimen may be utilised with all therapies set out in the present invention.
• the combination use with corticosteroids may in embodiments be used with the single dose regimen.
• the multi-day regimen may be utilised with all therapies set out in the present invention.
• the corticosteroid may be administered daily on the same day(s) as administering a compound according to the present invention.
• the corticosteroid may be administered on one or more subsequent days.
• the corticosteroid may be administered on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more subsequent days.
• the corticosteroid may be administered at a higher dose when administered on the same day(s) as a compound according to the present invention and at a lower dose on subsequent days.
• the corticosteroid may be dexamethasone.
• the compound according to the present invention may be administered at a dose according to the present invention on days 1-3 of the dosage regimen.
• the corticosteroid may be administered intravenously on days 1-3 of the dosage regimen.
• the corticosteroid may thereafter be administered by oral administration or IV from Day 4 and up to Day 10 (as per physician judgement according to patient clinical condition and evolution).
• the corticosteroid may be dexamethasone.
• the dose may be 6.6 mg/day IV on Days 1 to 3 (for example 8 mg dexamethasone phosphate), followed by dexamethasone 6 mg/day (for example 7.2 mg dexamethasone phosphate or 6 mg dexamethasone base) oral administration or IV from Day 4 and up to Day 10.
• dexamethasone is dexamethasone phosphate and is administered at a dose of 8 mg/day IV on Days 1 to 3, followed by dexamethasone 7.2 mg/day oral administration or IV from Day 4 and up to Day 10.
• the compound according to the present invention may be administered as an infusion, preferably a 1 hour infusion, a 1.5 hour infusion, a 2 hour infusion, a 3 hour infusion or longer; particularly preferably a 1.5 hour infusion.
• the regimen may be 1.5 mg of plitidepsin administered as a 1.5-hour infusion, once a day for 3 consecutive days; or 2 mg of plitidepsin administered as a 1.5-hour infusion, once a day for 3 consecutive days; or 2.5 mg of plitidepsin administered as a 1.5-hour infusion, once a day for 3 consecutive days; or 1 mg of plitidepsin administered as a 1.5-hour infusion, once a day for 5 consecutive days; or 2 mg of plitidepsin administered as a 1.5-hour infusion, once a day for 5 consecutive days.
• the regimen may be 7.5 mg of plitidepsin administered as a 1.5-hour infusion, as a single dose on day 1.
• the compound according to the present invention may be administered using a loading dose and a maintenance dose.
• the regimen according to the present invention may be: a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 2 mg/day for subsequent days; a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 1.5 mg/day for subsequent days; a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 0.5 mg/day for subsequent days; a loading dose of 2 mg for day 1, and followed by a maintenance dose of 1.5 mg/day for subsequent days; a loading dose of 2 mg for day 1 , and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 2 mg for day 1, and followed by a maintenance dose of 0.5 mg/day for subsequent days; a loading dose of 1.5 mg for day 1, and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 1.5 mg for day 1, and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 1.5
• the compound according to the present invention may be administered in combination with a corticosteroid.
• the corticosteroid may be administered on the same day(s) as administration of the compound.
• the corticosteroid may also be administered on one or more subsequent days.
• the corticosteroid is administered with the compound on days 1-3 and the corticosteroid is further administered on one or more of days 4-10.
• the corticosteroid may be administered intravenously on days when the compound is administered but administered by oral administration or IV on subsequent days.
• the corticosteroid may be dexamethasone.
• Dexamethasone may be administered at a dose of 6.6 mg/day IV on days when the compound is administered.
• Dexamethasone may be administered at a dose of 6 mg/day oral administration or IV on subsequent days, preferably one or more of days 4, 5, 6, 7, 8, 9 and 10.
• the dexamethasone dose as defined herein refers to the base weight.
• the dose can therefore be adjusted if used in salt form.
• the dexamethasone may be dexamethasone phosphate such that 8 mg/day is equivalent to 6.6 mg of dexamethasone base, and 7.2 mg/day is equivalent to 6 mg of dexamethasone base.
• the compound according to the present invention may be administered 1.5 mg/day intravenous (IV) combined with dexamethasone 6.6 mg/day IV on Days 1 to 3, followed by dexamethasone 6 mg/day oral administration (PO)/IV from Day 4 and up to Day 10 (as per physician judgement according to patient clinical condition and evolution).
• IV intravenous
• PO dexamethasone 6 mg/day oral administration
• the compound according to the present invention may be administered 2.0 mg/day intravenous (IV) combined with dexamethasone 6.6 mg/day IV on Days 1 to 3, followed by dexamethasone 6 mg/day oral administration (PO)/IV from Day 4 and up to Day 10 (as per physician judgement according to patient clinical condition and evolution).
• IV intravenous
• PO dexamethasone 6 mg/day oral administration
• the compound according to the present invention may be administered 2.5 mg/day intravenous (IV) combined with dexamethasone 6.6 mg/day IV on Days 1 to 3, followed by dexamethasone 6 mg/day oral administration (PO)/IV from Day 4 and up to Day 10 (as per physician judgement according to patient clinical condition and evolution).
• IV intravenous
• PO dexamethasone 6 mg/day oral administration
• the corticosteroid may be administered 20 to 30 minutes prior to starting treatment with the compound as defined herein.
• the patient may additionally receive the following medications, preferably 20 to 30 minutes prior to starting treatment with the compound according to the present invention:
• patients may receive ondansetron (or equivalent) 4 mg twice a day PO.
• patients When administered as a single dose, patients may receive the following prophylactic medications 20-30 minutes prior to plitidepsin infusion:
• Ondansetron 4 mg orally may be given every 12 hours for 3 days after plitidepsin administration to relieve drug-induced nausea and vomiting. If plitidepsin is administered in the morning the patient may receive the first dose of ondansetron in the afternoon.
• FIG. 1 shows that NF-KB transactivation in response to the activation of Toll -like receptors is inhibited by PLD.
• Human monocytic cells TNF-1 were stably transfected with a NF-kB -Luc plasmid and (A) levels of NF-kB transactivation measured in the presence and absence of PLD.
• B Compound-induced cytotoxicity was tested by the MTT cell proliferation assay. Cultures were exposed to PLD at lOOnM for 6 hours. RQ - Resiquimod at lOpg/mL.
• LPS-B5 Lipopolysaccharide from Escherichia coli 055:B5 (LPS-B5) at 10pg/mL.
• Poly-C - Polyinosinic- polycytidylic at 500pg/mL.
• TNF-a was used as a positive control. *** p ⁇ 0.001; ** p ⁇ 0.01
• FIG. 2 shows that Plitidepsin negatively regulates TLR-trigged cytokine secretion.
• NF-KB transactivation in response to the activation of Toll-like receptors leads to increased secretion of the pro-inflammatory cytokines: IL-l(a), IL-6 (b), IL-8 (c) and TNF-a (d).
• Cultures were exposed to PLD at lOOnM or DMSO for 6 hours. At 6 hours post-treatment secreted cytokines were analysed by ELISA. TNF-a was used as a positive control.
• Figure 3 shows the ex-vivo down-regulation of cytokines IL-6, IL-10 and TNF-a by PLD.
• Figure 4 shows a decrease in classically activated macrophages in LPS-challenged mice.
• Figure 5 shows the effects of plitidepsin on alveolar macrophage recruitment in LPS treated mice. Concentration-time curves (mean+SD) of plitidepsin in plasma and lung of mice(a), rats (b) and hamsters (c) after a single intravenous dose at 1.0, 0.2 and 0.2 mg/kg respectively.
• Figure 6 shows the inflammatory profile in the BALF of mice infected with influenza virus with (PR8) or without (PC) treatment with PLD.
• Figure 7 shows the titre of influenza virus in the lung of mice with or without treatment with PLD.
• the antiviral activity of PLD was quantified by qPCR measuring the mRNA level of viral NP (NP- PR8).
• Figure 8 shows a quantitative measurement of the level of immune cell infiltration, particularly AMs (alveolar macrophages) in the BALF of influenza infected mice treated with (PR8) or without (PC) PLD.
• AMs alveolar macrophages
• FIG 9 shows WNV-GFP infection efficiency in VeroE6 cells.
• Plitidepsin dose-response curves for infection efficiency GFP; green line
• DAPI cell biomass
• FIG 10 shows WNV-GFP infection efficiency in Huh-7 cells.
• Plitidepsin dose-response curves for infection efficiency GFP; green line
• DAPI cell biomass
• Figure 11 shows the impact of plitidepsin on WNV extracellular infectivity titers.
• Figure 12 shows the impact of plitidepsin on intracellular WNV RNA levels.
• Figure 13 shows the effect of plitidepsin (APL) pre -treatment at InM, lOnM and 50 nM on secretion of the pro-inflammatory cytokines IL6 (a), IL8 (b), PHb (c) and TNF-a (d).
• APL plitidepsin
• FIG. 13 shows the effect of plitidepsin (APL) pre -treatment at InM, lOnM and 50 nM on secretion of the pro-inflammatory cytokines IL6 (a), IL8 (b), PHb (c) and TNF-a (d).
• (e) shows the effect of InM, lOnM and 50 nM PLD treatment on cell viability (as a percent of control).
• THP-1 cells were treated with InM, lOnM or 50nM APL or DMSO (0.2%) followed by stimulus with Resiquimod at 2.5 or 5pg/mL at 8 hours.
• Resiquimod at
• Figure 14 shows the effect of plitidepsin treatment on the production of the pro-inflammatory cytokines, IL-6 (c), IL-10 (d) and TNF-a (e) mediated by LPS-B5 in CD45 + cells isolated from bronco-alveolar lavages (BALF).
• (a) shows the percent of CD45 + live cells in control, LPS-B5 and LPS-B5 and PLD treated cells
• (b) shows cell survival as a percent of control in LPS-B5 and LPS-B5 and PLD treated cells.
• Figure 15 shows the effect of plitidepsin treatment on the production of the pro-inflammatory cytokines TNF-a mediated by Resiquimod.
• Figures 16 and 17 show total plasma concentration profiles vs. time predicted for dosing schedules and administration according to the present invention.
• Figure 18 shows total plasma concentration profiles vs. time predicted for further dosing schedules and administration according to the present invention.
• Figure 19 shows total vs. plasma concentration profiles for single dose plitidepsin 7.5 mg and 1.5, 2.0 and 2.5 mg on day 1 to 3, using a 1.5 hour infusion.
• treating means reversing, attenuating, alleviating or inhibiting the progress of the disease or condition to which such term applies, or one or more symptoms of such disorder or condition.
• treating as used herein may also include prophylactic treatment.
• Treat”, “treating”, and “treatment” in the context of a viral infection may refer to one or more of the following: 1) reduction in the number of infected cells; 2) reduction in the number of virions present in the serum, including reduction in viral titre (which can be measured by qPCR); 3) inhibition (i.e., slowing to some extent, preferably stopping) the rate of viral replication; 4) reduction in the viral RNA load; 5) reduction in the viral infectivity titre (the number of virus particles capable of invading a host cell); and 6) relieving or reducing to some extent one or more of the symptoms associated with the viral infection. This may include inflammation associated with viral infection.
• Patient includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
• non-human mammals e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like
• non-mammals e.g., birds, and the like.
• the patient my require hospitalisation for management of the infection.
• Plitidepsin is a cyclic depsipeptide originally isolated from the marine tunicate Aplidium albicans. PLD is also known as Aplidin or Aplidine. Such terms are used interchangeably herein. PLD analogues are those analogues as defined herein as compounds of Formula I, II or III. In a preferred embodiment, the present invention relates to the use of PLD.
• WNV West Nile virus
• ssRNA single-stranded RNA
• the genome is translated as a single polyprotein, and subsequent cleavage of this polyprotein by viral and host proteases generates 10 viral proteins.
• WNV pathogenesis follow three phases, the early phase initial infection and spread (the early phase), peripheral viral amplification (the visceral-organ dissemination phase) and neuroinvasion (the central nervous system (CNS) phase).
• WNV The early phase after subcutaneous infection is defined by WNV replication in keratinocytes and skin-resident DCs, followed by viral amplification within the draining lymph node, which results in viremia and spread to visceral organs.
• the specific target cells for WNV infection are not well defined, but are thought to be subsets of DCs, macrophages and possibly neutrophils.
• WNV invasion of the CNS tissues constitutes the third phase of the infection. WNV may enter the brain though a combination of mechanisms that facilitates viral neuroinvasion, such as direct infection with or without a breakdown of the blood-brain barrier (BBB) and/or virus transport along peripheral neurons.
• BBB blood-brain barrier
• WNV pathogenesis A major hallmark of WNV pathogenesis is neuroinflammation, which is caused by exaggerated innate and acquired immune response. Accumulation of inflammatory monocytes into the brain and their differentiation to macrophages and microglia can also worsen neuroinflammation and CNS injury, as demonstrated in a murine model of nonlethal WNV infection. Recognition of WNV nucleic acid in monocytes/microglia by TLRs may lead to the production of TNF-a, which results in a loss of tight junctions, allowing the entry of WNV and immune cells into the perivascular space of the brain in mice.
• WNV monocyte/macrophage system
• activation of cells of the monocyte/macrophage system by WNV appears to result in important neuropathological consequences, and exaggerated innate responses may cause inflammation, altering the blood brain barrier permeability and allowing the virus to enter the CNS.
• treatment of infected neuronal cells with antibodies blocking TNF-a and other pro-inflammatory mediators results in a significant reduction of WNV- mediated neuronal death, suggesting that such mediators play a major role in the pathogenesis of WNV infection in the CNS.
• Orthomyxoviridae is a family of negative-sense RNA viruses and contains significant pathogens of both humans and animals. There are seven genera in the family, including Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogotovirus, Quaranjavirus, and Isavirus
• influenza viruses There are four classes of influenza viruses: A, B, C and D, with influenza virus A and B in particular causing winter epidemics of flu, causing around 300 to 650 thousand deaths a year.
• Influenza A viruses are of particular clinical significance as they have been the cause of a number of flu pandemics where many countries have been affected by large outbreaks.
• Influenza A viruses are are negative-sense, single-stranded, segmented RNA viruses that are divided into subtypes based on two proteins on the surface of the virus: hemagglutinin (H) and neuraminidase (N).
• the invention relates to the human influenza viruses, and in particular the H1N1, H1N2 and H3N2 sub-types of Influenza A and the Victoria and Yamagata lineages of Influenza B.
• Flu is characterized by a mild to severe disease which symptoms include high fever, runny nose, sore throat, muscle and joint pain, headache, coughing and tiredness, although vomiting and diarrhea can also occur in children infected with the virus.
• These symptoms typically appear one to four days after exposure and are generally self-limiting, however in some cases, particularly in those with weaker immune systems, complications such as pneumonia and sepsis can occur.
• cytokine storm Severe influenza infection has been associated with significant pathological changes in pulmonary tissues associated with heightened levels of inflammatory cytokines and chemokines. This exuberant immune response, known as the cytokine storm, is associated with high levels of pro-inflammatory cytokines and widespread tissue damage. In fact, the term “cytokine storm” was first coined when describing the immune response to influenza-associated encephalopathy.
• influenza infection of epithelial cells in the respiratory tract leads to a wave of inflammatory cytokine production from these cells, driving various interferon-regulated genes that go on to cause further downstream cytokine production through activation of innate immune cells such as macrophages, neutrophils and dendritic cells which, in severe cases, can proceed to cause tissue damage and chronic inflammation. It is this positive feedback loop of inflammation that can result in complications relating to influenza infection, and can ultimately result in death for patients most severely affected.
• Alkyl groups may be branched or unbranched, and preferably have from 1 to about 12 carbon atoms. One more preferred class of alkyl groups has from 1 to about 6 carbon atoms. Even more preferred are alkyl groups having 1, 2, 3 or 4 carbon atoms. Methyl, ethyl, n-propyl, isopropyl and butyl, including n-butyl, tert-butyl, sec-butyl and isobutyl are particularly preferred alkyl groups in the compounds of the present invention. As used herein, the term alkyl, unless otherwise stated, refers to both cyclic and noncyclic groups, although cyclic groups will comprise at least three carbon ring members.
• alkenyl and alkynyl groups in the compounds of the present invention may be branched or unbranched, have one or more unsaturated linkages and from 2 to about 12 carbon atoms.
• One more preferred class of alkenyl and alkynyl groups has from 2 to about 6 carbon atoms. Even more preferred are alkenyl and alkynyl groups having 2, 3 or 4 carbon atoms.
• Suitable aryl groups in the compounds of the present invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups.
• Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms.
• Preferably aryl groups contain from 6 to about 10 carbon ring atoms.
• Specially preferred aryl groups include substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted phenanthryl, and substituted or unsubstituted anthryl.
• Suitable heterocyclic groups include heteroaromatic and heteroalicyclic groups containing from 1 to 3 separated or fused rings and from 5 to about 18 ring atoms.
• Preferably heteroaromatic and heteroalicyclic groups contain from 5 to about 10 ring atoms, most preferably 5, 6 or 7 ring atoms.
• Suitable heteroaromatic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., coumarinyl including 8- coumarinyl, quinolyl including 8-quinolyl, isoquinolyl, pyridyl, pyrazinyl, pyrazolyl including pyrazol-3-yl, pyrazol-4-yl and pyrazol-5-yl, pyrimidinyl, furanyl including furan-2-yl, furan-3- yl, furan-4-yl and furan-5-yl, pyrrolyl, thienyl, thiazolyl including thiazol-2-yl, thiazol-4-yl and thiazol-5-yl, isothiazolyl, thiadiazolyl including thiadiazol-4-yl and thiadiazol-5-yl, triazolyl, tetrazolyl, isoxazo
• Suitable heteroalicyclic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidinyl including piperidin-3-yl, piperidin-4-yl and piperidin-5-yl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridyl, 2-pyrrolinyl, 3- pyrrolinyl, dihydropyrrolyl
• Suitable halogen substituents in the compounds of the present invention include F, Cl, Br and I.
• salts refers to any salt which, upon administration to the patient is capable of providing (directly or indirectly) a compound as described herein. It will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts.
• the preparation of salts can be carried out by methods known in the art. For instance, pharmaceutically acceptable salts of compounds provided herein are synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of the two.
• nonaqueous media like ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
• acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and -tolucncsulfonatc.
• alkali addition salts include inorganic salts such as, for example, sodium, potassium, calcium and ammonium salts, and organic alkali salts such as, for example, ethylenediamine, ethanolamine, /V,/V-di alkyl diethanolamine, triethanolamine and basic amino acids salts.
• the compounds of the invention may be in crystalline form either as free compounds or as solvates (e.g. hydrates, alcoholates, particularly methanolates) and it is intended that both forms are within the scope of the present invention. Methods of solvation are generally known within the art.
• the compounds of the invention may present different polymorphic forms, and it is intended that the invention encompasses all such forms
• Any compound referred to herein is intended to represent such specific compound as well as certain variations or forms.
• compounds referred to herein may have asymmetric centres and therefore exist in different enantiomeric or diastereomeric forms.
• any given compound referred to herein is intended to represent any one of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, and mixtures thereof.
• stereoisomerism or geometric isomerism about the double bond is also possible, therefore in some cases the molecule could exist as (£)- isomer or (Z)-isomer ( trans and cis isomers).
• each double bond will have its own stereoisomerism, that could be the same or different than the stereoisomerism of the other double bonds of the molecule.
• compounds referred to herein may exist as atropisomers. All the stereoisomers including enantiomers, diastereoisomers, geometric isomers and atropisomers of the compounds referred to herein, and mixtures thereof, are considered within the scope of the present invention.
• R 5 , R 9 , Rn, and R 15 are independently selected from hydrogen and substituted or unsubstituted CVO, alkyl. More preferred Ri, R 5 , R 9 , Rn, and R 15 are independently selected from hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl and substituted or unsubstituted butyl, including substituted or unsubstituted n-butyl, substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl, and substituted or unsubstituted sec-butyl.
• substituents may be chosen from the foregoing list.
• Hydrogen, methyl, n-propyl, isopropyl, isobutyl, sec -butyl, 4-aminobutyl, 3-amino-3-oxopropyl, benzyl, p-methoxybenzyl, p-hydroxybenzyl, and cyclohexylmethyl are the most preferred Ri, R 5 , R 9 , Rn, and R 15 groups.
• particularly preferred Ri is selected from sec -butyl and isopropyl, being sec -butyl the most preferred.
• Particularly preferred R 5 is selected from isobutyl and 4-aminobutyl, being isobutyl the most preferred.
• Particularly preferred Rn is methyl and isobutyl.
• Particularly preferred R 9 is selected from p-methoxybenzyl, p- hydroxybenzyl, and cyclohexylmethyl, being p-methoxybenzyl the most preferred.
• Particularly preferred Rn is selected from methyl, n-propyl, and benzyl, being methyl and benzyl the most preferred.
• particularly preferred Ri, R 5 , R 9 , and R 15 are independently selected from hydrogen and substituted or unsubstituted CVO, alkyl.
• R 5 , R 9 , and Ri 5 are independently selected from hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl and substituted or unsubstituted butyl, including substituted or unsubstituted n-butyl, substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl, and substituted or unsubstituted sec -butyl.
• substituents may be chosen from the foregoing list.
• Hydrogen, methyl, n-propyl, isopropyl, isobutyl, sec -butyl, 4-aminobutyI, 3-amino-3-oxopropyI, benzyl, p-methoxybenzyl, p-hydroxybenzyl, and cyclohexylmethyl are the most preferred Ri, R 5 , R 9 , and R 15 groups.
• particularly preferred Ri is selected from sec-butyl and isopropyl, being sec -butyl the most preferred.
• Particularly preferred R 5 is selected from isobutyl and 4-aminobutyI, being isobutyl the most preferred.
• Particularly preferred R 9 is selected from p-methoxybenzyl, p-hydroxybenzyl, and cyclohexylmethyl, being p- methoxybenzyl the most preferred.
• Particularly preferred R 15 is selected from methyl, n-propyl, and benzyl, being methyl and benzyl the most preferred.
• Rs, Rio, R 12 , and Ri6 are independently selected from hydrogen and substituted or unsubstituted CVO, alkyl. More preferred Rs, Rio, R 12 , and R 1 ⁇ 2 are independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl and butyl, including n-butyl, tert-butyl, isobutyl and sec-butyl, and even more preferred they are independently selected from hydrogen and methyl. Specifically, particularly preferred Rs, RI O and R 12 are methyl, and particularly preferred R 1 ⁇ 2 is hydrogen.
• R 3 and R 4 are independently selected from hydrogen and substituted or unsubstituted CVO, alkyl. More preferred R 3 and R 4 are independently selected from hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, and substituted or unsubstituted butyl, including substituted or unsubstituted n-butyl, substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl and substituted or unsubstituted sec-butyl.
• substituents may be chosen from the foregoing list.
• Hydrogen, methyl, isopropyl, and sec-butyl are the most preferred R 3 and R 4 groups.
• particularly preferred R 3 is selected from methyl and isopropyl and particularly preferred R 4 is methyl or hydrogen.
• R 6 and R 7 are independently selected from hydrogen and substituted or unsubstituted CVO, alkyl. More preferred R 7 is selected from hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl and substituted or unsubstituted butyl, including substituted or unsubstituted n-butyl, substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl, and substituted or unsubstituted sec-butyl.
• R 6 is selected from hydrogen, methyl, ethyl, n-propyl, isopropyl and butyl, including n- butyl, tert-butyl, isobutyl and sec-butyl. Most preferred R 6 is selected from hydrogen and methyl and most preferred R 7 is methyl.
• R 6 and R 7 together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted heterocyclic group.
• preferred heterocyclic group is a heteroalicyclic group containing one, two or three heteroatoms selected from N, O or S atoms, most preferably one N atom, and having from 5 to about 10 ring atoms, most preferably 5, 6 or 7 ring atoms.
• a pyrrolidine group is the most preferred.
• R 13 and Ri 4 are independently selected from hydrogen and substituted or unsubstituted CVO, alkyl. More preferred R 13 is selected from hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl and substituted or unsubstituted butyl, including substituted or unsubstituted n-butyl, substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl, and substituted or unsubstituted sec-butyl.
• R M is selected from hydrogen, methyl, ethyl, n-propyl, isopropyl and butyl, including n-butyl, tert-butyl, isobutyl and sec-butyl.
• Most preferred R 13 is selected from hydrogen, methyl, isopropyl, isobutyl, and 3-amino-3-oxopropyl and most preferred R M is hydrogen.
• R and R M together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted heterocyclic group.
• preferred heterocyclic group is a heteroalicyclic group containing one, two or three heteroatoms selected from N, O or S atoms, most preferably one N atom, and having from 5 to about 10 ring atoms, most preferably 5, 6 or 7 ring atoms.
• a pyrrolidine group is the most preferred.
• R2 is selected from hydrogen, substituted or unsubstituted C 1 -G, alkyl, and COR a , wherein R a is a substituted or unsubstituted C I -C , alkyl, and even more preferred R a is methyl, ethyl, n-propyl, isopropyl and butyl, including n-butyl, tert-butyl, sec-butyl and isobutyl. More preferably R2 is hydrogen.
• substituents may be chosen from the foregoing list.
• Hydrogen, COR a , COOR a , and SO2R C are the most preferred Rn groups, and hydrogen, COObenzyl, CObenzo[b]thiophen-2-yl, SC>2(p- methylphenyl), COCOCH3 and COOC(CH3)3 are even most preferred.
• Y is CO. In another embodiment, it is particularly preferred that Y is -COCH(CH3)CO-.
• X is O. In another embodiment, it is particularly preferred that X is NH.
• n, p and q are 0. In another embodiment, it is particularly preferred that n is 1 and p and q are 0. In another embodiment, it is particularly preferred that n and p are 1 and q is 0. In another embodiment, it is particularly preferred that n, p, and q are 1. In another embodiment, it is particularly preferred that n and p are 1 and q is 2.
• p and q are 0. In another embodiment, it is particularly preferred that p is 1 and q is 0. In another embodiment, it is particularly preferred that p and q are 1. In another embodiment, it is particularly preferred that p is 1 and q is 2.
• the preferences described above for the different substituents are combined.
• the present invention is also directed to such combinations of preferred substitutions of formula I, II and III above.
• R a , R b , and R c present in the compounds of the invention, and unless it is stated explicitly so, it should be understood that they can be each independently different within the given definition, i.e. R a does not represent necessarily the same group simultaneously in a given compound of the invention.
• R a does not represent necessarily the same group simultaneously in a given compound of the invention.
• compounds of general formula I, II and III when q takes a value of 2 there are two groups Ris and two groups Ri 6 in the compound. It is hereby clarified that each Ris and each Ri 6 group in a given compound may be independently selected among the different possibilities described above for such groups.
• a particularly preferred stereochemistry for compounds of general formula I is wherein X, Y, n, p, q, and Ri-Rn are as defined above, and when Y is -COCH(CH3)CO- it has the following stereochemistry:
• a particularly preferred stereochemistry for compounds of general formula II is wherein X, Y, n, p, q, Ri, R2, and R5-R17 are as defined above, and when Y is -COCH(CH3)CO- it has the following stereochemistry: wherein X, Y, p, q, R1-R10, and R12-R17 are as defined above, and when Y is -COCH(CH3)CO- it has the following stereochemistry:
• Particularly preferred compounds of the invention are the following:
• the compounds of general formula I, II and III may be prepared following any of the synthetic processes disclosed in Vera et al. Med. Res. Rev. 2002, 22(2), 102-145, WO 2011/020913 (see in particular Examples 1-5), WO 02/02596, WO 01/76616, and WO 2004/084812, which are incorporated herein by reference.
• the preferred compound is PLD or pharmaceutically acceptable salts or stereoisomers thereof. Most preferred is PLD.
• plitidepsin is (-)-(3S,6R,7S,10R,llS,15S,17S,20S,25aS)-ll-hydroxy-3- (4-methoxybenzyl)-2,6, 17 -trimethyl- 15-( 1 -methylethyl)-7 - [[(2R)-4-methyl-2- [methylf [(2S)- 1 -
• Plitidepsin is a cyclic depsipeptide originally isolated from a Mediterranean marine tunicate ( Aplidium albicans ) and currently manufactured by full chemical synthesis. It is licensed and marketed in Australia under the brand name plitidepsin for the treatment of multiple myeloma.
• the present invention provides the use of a compound of the present invention in the treatment of a viral infection, wherein the vims is selected from the Orthomyxoviridae family or wherein the vims is West Nile vims.
• a compound of the present invention for use in the treatment of viral infection, wherein the virus is selected from the Orthomyxoviridae family or wherein the virus is West Nile vims.
• a compound of the present invention in the manufacture of a medicament for the treatment of viral infection, wherein the vims is selected from the Orthomyxoviridae family or wherein the vims is West Nile vims.
• a method for the treatment of a viral infection wherein the vims is selected from the Orthomyxoviridae family or wherein the vims is West Nile vims, wherein the method comprises administering to an individual in need thereof a therapeutically effective amount of a compound of the present invention.
• the infection may also be characterised by excessive or increased production or secretion of one or more pro-inflammatory cytokines, and preferably at least one of IL-12, IL-10, IL-1, IL-6, IL- 8, CCL-2 and TNF-a and more preferably at least one of IL-1, IL-6, IL-8 and TNF-a.
• pro-inflammatory cytokines preferably at least one of IL-12, IL-10, IL-1, IL-6, IL- 8, CCL-2 and TNF-a and more preferably at least one of IL-1, IL-6, IL-8 and TNF-a.
• the compound of the invention may be further administered in combination with an (a different) anti-viral agent.
• the anti-viral agent may be administered concurrently, sequentially or separately to administration of a compound of the invention.
• the compound of the invention may be used as an anti-inflammatory to treat inflammation or hyperinflammation associated or as a consequence of the viral infection.
• a compound as defined herein for use in the treatment of a disorder caused by a virus selected from the Orthomyxoviridae family or wherein the virus is West Nile virus, wherein the disorder is selected from neuroinflammation, pneumonia and immunopathology, in particular hypercytokinemia (cytokine storm syndrome), and sepsis.
• the disorder is immunopathology and in particular, hypercytokinemia.
• a compound as defined herein for use in the treatment of pneumonia and immunopathology, caused by influenza, in particular hypercytokinemia (cytokine storm syndrome), and sepsis.
• a compound as defined herein in the manufacture of a medicament for the treatment of pneumonia and immunopathology, caused by influenza, in particular hypercytokinemia (cytokine storm syndrome), and sepsis.
• a method for the treatment of pneumonia and immunopathology, caused by influenza, in particular hypercytokinemia (cytokine storm syndrome) and sepsis comprising administering to an individual in need thereof a therapeutically effective amount of a compound as defined herein.
• the disorder is immunopathology and in particular, hypercytokinemia.
• a compound as defined herein for use in the treatment of neuroinflammation or immunopathology, caused by West Nile virus, in particular hypercytokinemia (cytokine storm syndrome), and sepsis.
• a compound as defined herein in the manufacture of a medicament for the treatment of neuroinflammation or immunopathology, caused by West Nile virus, in particular hypercytokinemia (cytokine storm syndrome), and sepsis.
• a method for the treatment neuroinflammation or immunopathology, caused by West Nile virus, in particular hypercytokinemia (cytokine storm syndrome) and sepsis comprising administering to an individual in need thereof a therapeutically effective amount of a compound as defined herein.
• the disorder is immunopathology and in particular, hypercytokinemia.
• the Orthomyxoviridae virus is selected from Influenzavirus A, Tnfluenzavirus B, Tnfluenzavirus C, Thogotovirus, Quaranjavirus, and Isavirus.
• the Orthomyxoviridae virus is Influenza A, preferably selected from H1N1, H1N2 and H3N2 sub- types.
• the Orthomyxoviridae virus is influenza B, preferably selected from the Yamagata or Victoria lineages.
• the West Nile virus is selected from lineage 1, 2, 3, 4, 5, 6, 7 or 8.
• the virus is lineage 1 or 2 (WNV-1 or WNV-2).
• compositions having biological/pharmacological activity may be used in pharmaceutical compositions having biological/pharmacological activity for the treatment of the above mentioned conditions.
• These pharmaceutical compositions comprise a compound of the invention together with a pharmaceutically acceptable carrier.
• carrier refers to a diluent, adjuvant, excipient or vehicle with which the active ingredient is administered. Suitable pharmaceutical carriers are described in “Remington’s Pharmaceutical Sciences” by E. W. Martin, 1995.
• Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions, emulsions, etc.) compositions for oral, topical or parenteral administration.
• Pharmaceutical compositions containing compounds of the invention may be delivered by liposome or nanosphere encapsulation, in sustained release formulations or by other standard delivery means.
• compositions as described in W09942125 are in the form of powder for solution for infusion.
• a lyophilised preparation of a compound of the invention including water-soluble material and secondly a reconstitution solution of mixed solvents.
• a particular example is a lyophilised preparation of PLD and mannitol and a reconstitution solution of mixed solvents, for example PEG-35 castor oil, ethanol and water for injections.
• Each vial for example may contain 2 mg of PLD.
• each mL of reconstituted solution may contain: 0.5 mg of PLD, 158 mg of PEG-35 castor oil, and ethanol 0.15 mL/mL.
• the specific dosage and treatment regimen for any particular patient may be varied and will depend upon a variety of factors, including the activity of the specific compound employed, the particular formulation being used, the mode of application, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, reaction sensitivities, and the severity of the particular disease or condition being treated.
• the compounds of the present invention may be administered according to a dosing regimen of a daily dose.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose.
• the compounds of the present invention may be administered according to a dosing regimen of a daily dose for 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day.
• Preferred regimen is 2-5 days, or 3-5 days, or 3, 4 or 5 days, most preferably 3 days or 5 days.
• the dose may be a dose of 5mg a day or less, 4.5mg a day or less, 4mg a day or less, 3.5mg a day or less, 3mg a day or less, 2.5mg a day or less or 2mg a day or less.
• Particular doses include 0.5 mg/day, 1 mg/day, 1.5 mg/day, 2 mg/day, 2.5 mg/day, 3 mg/day, 3.5 mg/day, 4 mg/day, 4.5 mg/day, or 5mg/day.
• Preferred doses are 1 mg/day, 1.5 mg/day, 2 mg/day and 2.5 mg/day.
• the compounds of the present invention may be administered according to a total dose of 1-50 mg, 1-40 mg, 1-30 mg, 1-20 mg, 1-15 mg, 3-15 mg, 3-12 mg, 4-12 mg, 4- 10 mg, or 4.5-10 mg.
• Total doses may be 4mg, 4.5mg, 5mg, 5.5mg, 6mg, 6.5mg, 7mg, 7.5mg, 8mg, 8.5mg, 9mg, 9.5mg or lOmg.
• Preferred total doses are 4.5mg, 5mg, 6mg, 7.5mg, 8mg, 9mg or lOmg.
• the total dose may be split over 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days, preferably 3 days or 5 days.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 5 days, at a dose of 2.5mg a day or less.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 5 days, at a dose of 2mg a day or less.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 1.5mg a day or less.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 2mg a day or less.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 2.5mg a day or less.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 1.5mg a day.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 2.0mg a day.
• the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 2.5mg a day. In a further embodiment, the compounds of the present invention may be administered according to a dosing regimen of a once daily dose for 3 days, at a dose of 1.5 to 2.5mg a day.
• An alternative regimen is a single dose on day 1.
• the single dose may be 1-10 mg, 4-10 mg, 4.5- 10 mg; 4mg, 4.5mg, 5mg, 5.5mg, 6mg, 6.5mg, 7mg, 7.5mg, 8mg, 8.5mg, 9mg, 9.5mg or lOmg; preferably 4.5mg, 5mg, 6mg, 7.5mg, 8mg, 9mg or lOmg; more preferably 5-9 mg, 6.5-8.5 mg, 7- 8 mg or 7.5 mg.
• the compounds of the present invention may be administered according to the present invention, wherein the compounds of the present invention are administered with a corticosteroid.
• the corticosteroid is dexamethasone.
• the corticosteroid may be administered daily with the compounds of the present invention. Administration may be sequential, concurrent or consecutive.
• the corticosteroid may be further administered on the days following administration of compounds according to the present invention. By way of example, with a 3 day dosing regimen, the corticosteroid may be administered on days 1-3 and then further administered daily for 3, 4, 5, 6, 7, 8, 9 or 10 or more further days.
• the corticosteroid may be administered is administered on days 1-3 as an intravenous administration and then on days 6-10 as an oral administration.
• the dosage of corticosteroid may be higher during the co-administration phase with the compounds of the present invention, and is lowered during the subsequent days.
• Particular dosing schedules include:
• patients may receive the following medications 20 to 30 minutes prior to starting the infusion with a compound according to the present invention:
• Dexamethasone 6.6 mg IV (which is included in the schedule above) Additionally, on Days 4 and 5 patients treated with compounds according to the present invention may receive ondansetron 4 mg twice a day PO.
• Doses of dexamethasone, ondansetron and ranitidine are herein defined on the basis of the base form.
• the dose of diphenhydramine hydrochloride is given on the basis of the hydrochloride salt.
• Doses of compounds of the invention are given on the basis of the base form.
• the daily doses may be administered as an infusion.
• the infusion may be a 1 hour infusion, a 1.5 hour infusion, a 2 hour infusion, a 3 hour infusion or longer.
• the infusion is 1.5 hours.
• the dose may be administered according to a regimen which uses a loading dose and a maintenance dose.
• Loading/maintenance doses according to the present invention includes: a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 2 mg/day for subsequent days; a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 1.5 mg/day for subsequent days; a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 2.5 mg for day 1, and followed by a maintenance dose of 0.5 mg/day for subsequent days; a loading dose of 2 mg for day 1, and followed by a maintenance dose of 1.5 mg/day for subsequent days; a loading dose of 2 mg for day 1 , and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 2 mg for day 1, and followed by a maintenance dose of 1 mg/day for subsequent days; a loading dose of 2 mg for day 1, and followed by a maintenance dose of 0.5 mg/day for subsequent days;
• the daily dose may be reduced in the final day or days of the regimen.
• the dose may be reduced to 1 mg on days 4 and 5.
• Particular regimens include: - lmg of plitidepsin administered as a 1.5-hour infusion, once a day for 5 consecutive days (total dose 5mg);
• plitidepsin administered as a 1.5-hour infusion, once a day for 5 consecutive days.
• the dose may be reduced to 1 mg / day on days 4 and 5 (total dose 8-10mg);
• a single dose regimen includes:
• the single dose regimen may further include the following prophylactic medications 20- 30 minutes prior to plitidepsin infusion:
• Ondansetron 4 mg orally may be given every 12 hours for 3 days after plitidepsin administration to relieve drug-induced nausea and vomiting. If plitidepsin is administered in the morning the patient may receive the first dose of ondansetron in the afternoon.
• patients may be selected for treatment with compounds of the present invention based on clinical parameters and/or patient characteristics. Suitable parameters may be measurements disclosed in the present application.
• the present invention is directed to a compound for use according to the present invention, wherein the compound is administered in combination with one or more of the following prophylactic medications: diphenhydramine hydrochloride, ranitidine, dexamethasone, ondansetron.
• diphenhydramine hydrochloride 25 mg iv or equivalent; Ranitidine 50 mg iv or equivalent; Dexamethasone 8 mg intravenous; Ondansetron 8 mg i.v. in slow infusion of 15 minutes or equivalent.
• Patients may receive said prophylactic medications 20-30 minutes before the infusion of plitidepsin.
• Dexamethasone 8 mg intravenous may be dexamethasone phosphate leading to 6.6 mg dexamethasone base.
• Compound 240 known as DidemninB and shown by the structure below:
• PLD inhibits in vitro the transactivation of NF-KB.
• THP-1 cells stably transfected with an NFKB luciferase reporter plasmid.
• TNFa an activator of NF-KB
• TLR3 ligand 500 pg/mL poly I:C
• TLR4 ligand 10 pg/mL LPS-B5
• TLR-7/8 ligand lOpg/mL Resiquimod
• PLD also inhibits in vitro the secretion of the pro-inflammatory cytokines IL-1, IL-6, IL-8 and TNF-alpha in human monocytes.
• THP- 1 cells treated THP- 1 cells with 100 ng/mL TNFa (an activator of NF-KB), 500 pg/mL poly I:C (TLR3 ligand), 10 pg/mL LPS-B5 (TLR4 ligand) or lOpg/mL Resiquimod (TLR-7/8 ligand).
• TNFa an activator of NF-KB
• TLR3 ligand poly I:C
• TLR4 ligand 10 pg/mL LPS-B5
• lOpg/mL Resiquimod TLR-7/8 ligand
• poly PC, LPS and Resiquimod induce the secretion of IL-1, IL-6, IL-8 and TNFa.
• plitidepsin clearly inhibited the production of IL-1, IL-6, IL-8 and TNFa.
• TNFa failed to increase the secretion of IL-1 and IL-6. It is possible that THP-1 cells need other TNFa exposure times to secret these cytokines.
• plitidepsin clearly inhibited the secretion of pro- inflammatory cytokines IL-1, IL-6, IL-8.
• PLD inhibits ex-vivo secretion of the pro-inflammatory cytokines, IL-6, IL-8 and TNF-alpha in murine isolated from BAL (Bronchoalveolar lavage).
• plitidepsin inhibits the LPS -trigged cytokine secretion in alveolar macrophages.
• mice were injected i.v. with plitidepsin (1 mg/kg) or vehicle and 12 hours after administration bronchoalveolar lavage fluid (BAL) was collected.
• BAL bronchoalveolar lavage fluid
• Cells were plated and treated ex-vivo or not with 15 pg/mL of LPS-B5 for 3 or 6 hours and secreted cytokines were measured.
• LPS induce the secretion of IL-6, IL-10 and TNFa (grey bars).
• the drug clearly inhibited the production of pro-inflammatory cytokines IL-6, and TNF-a induced by LPS (red bars) and led to an overall anti-inflammatory effect.
• Activated macrophages are twice the size of resting macrophages and are more “aggressive”, having increased levels of lysosomal proteins and a greater ability to phagocytose.
• Classically activated macrophages also release proteases, neutrophil chemotactic factors, reactive oxygen species and pro-inflammatory cytokines (such as IL-1 beta/IL-lF2, IL-6, and TNF-alpha/TNFSFlA), leading to inflammation and tissue destruction.
• cytokines such as IL-1 beta/IL-lF2, IL-6, and TNF-alpha/TNFSFlA
• PLD reduces the number of macrophages in BAL.
• mice treated mice with plitidepsin (1 mg/kg) i.v., with LPS (20 pg/kg) i.p. in sterile saline or with plitidepsin (1 mg/kg; i.v.) in combination with LPS (20 pg/kg. i.p.).
• LPS 20 pg/kg
• plitidepsin 1 mg/kg; i.v.
• bronchoalveolar lavages were collected. Bronchoalveolar lavage cells were obtained by centrifugation and analyzed by flow cytometry (Figure 4b). Upper panels show the strategy of analysis of macrophage population present in the samples. Lower right panel show the same result expressed as percentage of cells.
• PLD is distributed to the lungs in non-clinical species.
• similar plasma exposures are achieved in non-clinical the mouse (which is the nonclinical species used in the pharmacological modeIs)and patients.
• the concentration of plitidepsin in lungs was consistently higher than that in plasma at any sampling time, with a lung-to-plasma ratio (calculated as U " 1; A U Co- , / pl sm 'A UCo- , ) in mice, rats and hamsters of 133, 460 and 909, respectively, thus confirming the distribution of plitidepsin into the lung.
• Nonclinical species single intravenous bolus.
• NF-KB transactivation was assayed using the Bright-GloTM Luciferase Assay System following the manufacturer’s instructions.
• the compounds were used either alone or combined with 100 nM plitidepsin for 6 hours. Luminescence was measured in a Perkin-Elmer EnVision reader. A MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay was simultaneously performed to control the cytotoxicity of the compounds. Cell survival was expressed as percentage of control cell growth. The data presented are the average of three independent experiments performed in triplicate.
• THPI-NFKB-LUC cell cultures were treated as described above, and the culture medium was sampled at 6 hours post-treatment to assay for secreted cytokines by ELISA. Media samples were stored at 4°C.
• IL-8, IL-Ib, IL-6 and TNFD protein secretion into culture medium was quantitated using highly specific and sensitive ELISA kits.
• Human IL-lb, human IL-6, human IL-8 and human TNF OptEIATM ELISA kits were obtained from BD Biosciences and performed as described by the manufacturer. The data presented are the average of three independent experiments performed in triplicate.
• mice were randomized into groups of five animals to receive the treatments. Mice were injected intra venous (i.v.) with plitidepsin (1 mg/kg) and 12 hours after administration were euthanised. Control group received plitidepsin vehicle diluted with saline (Cremophor/Ethanol/Water). Bronchoalveolar lavage fluid (BAL) of each group was collected and centrifugated to obtain bronchoalveolar lavage cells. Cells underwent red blood cell lysis (Roche) and were plated and treated ex-vivo or not with 15 pg/mL of LPS-B5 for 3 or 6 hours.
• BAL Bronchoalveolar lavage fluid
• Mouse IL-6, mouse IL-10 and mouse TNF DuoSet ELISA kits were obtained from R&D Systems and performed as described by the manufacturer. Data presented here are representative from a series of at three independent experiments.
• mice were randomiced into groups of two animals to receive the treatments. Mice were challenged with plitidepsin (1 mg/kg) intra venous (i.v.), with LPS (20 pg/kg) intra peritoneal (i.p.) in sterile saline or with plitidepsin (1 mg/kg; i.v.) in combination with LPS (20 pg/kg, i.p.).
• the control group received plitidepsin vehicle (Cremophor/Ethanol/W ater) diluted with saline.
• animals were euthanised and bronchoalveolar lavage collected (a total of 1.2 ml, PBS). Bronchoalveolar lavage cells were obtained by centrifugation and analyzed by flow cytometry. Data presented here are representative from a series of at three independent experiments.
• mice were randomized into groups of two animals to receive the treatments. Mice were challenged with plitidepsin (1 mg/kg) intra venous (i.v.) followed by Resiquimod (50 pg/mouse, intranasal;) 1 hour latter. The control group received plitidepsin vehicle (Cremophor/Ethanol/Water) diluted with saline. One and 3 hours later, animals were euthanized, bronchoalveolar lavage collected (a total of 1.2 ml, PBS) and then, TNFa quantified by ELISA kits. Data presented here are representative from a series of at three independent experiments.
• Bronchoalveolar lavage cells were stained with anti- F4/80-BV510, CD45-APC700, CDllb- BV650, CD1 lc-APC-Fire, CD24-PC7 and Ly6C-BV605 monoclonal antibodies (Biolegend) and a LIVE/DEADTM Fixable Green Dead Cell Stain Kit, for 488 nm excitation (Thermofisher). Macrophages (F4/80+) were gated on alive immune cells (CD45+ LIVE/DEAD dye-), while alveolar macrophages (F4/80+ CD24-) were specifically gated on CDllc+ CD lib- population from alive immune cells. Isotype controls and compensation beads were used to set compensations and gating strategies.
• the aim here was to evaluate in vivo the effects of plitidepsin in the treatment of severe pneumonia caused by the mouse-adapted A/H1N1 influenza virus infection (A/Puerto Rico/8/34), and also on viral titre levels.
• mice Female mice at the age of 9 weeks were anesthetized by intraperitoneal injection of ketamine-xylazine solution and infection was performed by intranasal administration of virus solution PBS into 20 ul per nares.
• mice that were receiving the treatment were injected subcutaneously with 0.3 mg/kg or 0.15mg/kg of plitidepsin. Subsequently, survival and body weight loss was monitored until day 3 p.L. No death mice or mice with a weight loss of more than 30% of the starting body weight was recorded during the time of the treatment.
• FIG. 6 shows the inflammatory profile in the BALF of infected mice with or without treatment with plitidepsin.
• plitidepsin strongly reduced the levels of IL-6, CCL2, IL-la, IFN-g and TNF-a. Mice that were receiving only half-dose of the drug were less protected and showed an intermediated phenotype.
• the viral titer in the lungs was also assessed. As shown in Figure 7, plitidepsin reduced the viral titre in the lungs at both 0.3mg/kg and 0.15mg/kg.
• the BALF cellular composition is defined as a marker of lung immune response viral infection. Quantitative measurement of infiltrating cells in correlation to inflammatory cytokine levels was assessed in influenza infected mice. Treatment with plitidepsin did not reduce the total cellular composition of the BALF (CD45 + x 10 6 ). As shown in Figure 8 we also found an increase in alveolar macrophage (AM) infiltration suggesting that AMs contribute to viral clearance.
• AM alveolar macrophage
• target cell lines Vero-E6 and Fluh7 were inoculated with an infectious virus stock dilution in the presence of increasing concentrations of plitidepsin, starting at 2.3pM or 2.5pg/ml and using 4.5mM or 5pg/ml as the highest concentration. Infection efficiency was evaluated at 48 hours, after the virus has spread to a substantial fraction of the target cells in vehicle -treated cultures.
• Relative infection efficiency was assessed by automated fluorescence microscopy in the green channel and overall cell biomass/well was estimated by nuclear staining with DAPI in the blue channel, as a preliminary assessment of the compound effective doses as well as overall compound cytotoxicity.
• WNV-GFP infection efficiency rapidly decreased at doses around 5nM in VeroE6 cells, reaching background fluorescence levels at 36nM and above. The cell number remained unchanged up to 36nM, but significantly decreased at higher concentrations (180 nM; p ⁇ 0.05), suggesting that plitidepsin interferes with cell duplication capacity at concentrations above 36 nM.
• the estimated EC50 value for plitidepsin in VeroE6 cells is 4.9 nM and the EC90 is 9.5 nM. Based on the cell biomass the CC50 value is 2330 nM. Thus, the therapeutic index, expressed as the ratio CC50/EC50 in VeroE6 cells is 475.
• plitidepsin interferes with WNV-GFP propagation in cell culture infection models in both Vero-E6 and Fluh-7 cells.
• antiviral activity in the absence of measurable interference with cell viability may be observed at 1.5 nM (p ⁇ 0.05) in Fluh-7 cells and 7.2 nM (p ⁇ 0.05) in Vero-E6 cells.
• Vero-E6 or Fluh-7 cells were inoculated (MOI 0.01) with a recombinant virus based on the NY99 WNV strain. Infection was performed in the presence of the vehicle or a dose range of plitidepsin displaying bioactivity in the WNV- GFP model (45, 15, 5, 1.5 nM; see above). Inoculated cells were incubated for 48 hours, time at which samples of the supernatants were processed to determine infection efficiency by extracellular infectivity titration. In addition, total RNA was extracted from control and plitidepsin-treated cells to determine viral RNA load and independently assess overall viral infection efficiency.
• Extracellular infectivity titers show that the presence of plitidepsin strongly interfered with WNV propagation as shown in Figure 11, with reductions >3 orders of magnitude at 45nM in VeroE6 and Fluh-7 cells. This phenomenon is dose- dependent in both cell lines.
• Intracellular WNV RNA load was determined by RT-qPCR in control and plitidepsin- treated cells. Remarkably, as shown in Figure 12, no RNA could be recovered from Fluh-7 cells treated with 45nM plitidepsin. Nevertheless, viral RNA load was determined in the rest of the sample groups in both cell lines. In agreement with the trend exhibited by the extracellular infectivity titers, viral RNA load significantly decreased in a dose-dependent manner at 15 and 45nM in Vero-E6 cells, while the viral load at 5 and 1.5nM were not distinguishable from those in the control ( Figure 12). Similarly, Fluh-7 showed a marked reduction in viral load at 15nM, magnitude of which declined in a dose-dependent manner.
• the WNV infection propagation efficiency data suggest that plitidepsin interferes with viral replication at doses above 5nM in both Vero-E6 and Fluh-7 cells, although some degree of interference could be observed at lower concentrations in Fluh-7 cells.
• the results measuring overall propagation efficiency using functional (infectivity) as well as molecular (RT-qPCR) approaches confirm that plitidepsin reduces virus propagation efficiency in the expected range of concentrations based on the data obtained with WNV-GFP.
• DMSO dimethylsulfoxyde
• Cell culture Subconfluent Vero-E6 cells and Huh-7ceII cultures were maintained in complete media [(DMEM supplemented with 10 iTiM HEPES, lx non-essential amino acids (Gibco), 100 U / mL penicillin-streptomycin (Gibco) and 10% Fetal Bovine Serum (heat-inactivated at 56 °C for 30 min)].
• Viruses WNV (NY99) and WNV-GFP recombinant viruses were rescued from cloned cDNA as previously described. Stock infectivity titers were determined by plaque assay on Vero- E6 cells as previously described.
• infectivity titration infectivity titers were determined using endpoint dilution and immunofluorescence microscopy using a monoclonal antibody against Fla vi virus E protein (4G2; ATCC® HB-112TM). Briefly, Huh-7 cells were inoculated with supernatant dilutions in a 96-well format. Forty-eight hours post infection, cells were fixed for 30 minutes at room temperature with a 4% formaldehyde solution in PBS, washed twice with PBS and incubated with binding buffer (0.3% Triton X100, 3%BSA in PBS) for 1 hour.
• DAPI 4,6-diamidino-2-phenylindole; ThermoFisher
• Reverse-transcription and qPCR 60 ng of total cellular RNA were subjected to RT-qPCR using NZYSpeedy One-Step qPCR probe master mix, using manufacturer's recommendations and the primers.
• Figure 16 illustrates the simulation of the total plasma plitidepsin concentration profiles vs. time after a daily dose (D1-D5) of 1.0 mg and 2.0 mg.
• the horizontal black lines represent the total plasma concentrations associated with the concentrations in lung equivalent to exemplary IC50, IC90 and 3xIC90 in vitro values.
• a further dosage regimen is 1.5mg daily for 5 days.
• a further regimen is illustrated in Figure 17 which simulates plitidepsin total plasma concentrations associated to an initial flat dose of 1 mg (Day 1) given as a 1-h i.v. infusion, followed by daily doses of 0.5 mg (D2-D5).
• Figure 18 illustrates the simulation of the total plasma plitidepsin concentration profiles vs. time after a daily dose (D1-D3) of 1.5 mg, 2.0 mg and 2.5 mg.
• the horizontal black lines represent the total plasma concentrations associated with concentrations in lungs equivalent to exemplary IC50, IC90 and 3xIC90 in vitro values.
• Figure 19 shows a validated plitidepsin population pharmacokinetic model (Nalda-Molina R, et al. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. Cancer Chemother Pharmacol. 2009 Jun;64(l):97-108. doi: 10.1007/s00280-008-0841-4) to confirm total plasma concentration with a single dose.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Gastroenterology & Hepatology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pulmonology (AREA)
• Transplantation (AREA)
• AIDS & HIV (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (14)

Publications (2)

Family

ID=74732953

Family Applications (2)

Family Applications After (1)

Country Status (17)

Cited By (1)

Families Citing this family (4)

Citations (5)

Family Cites Families (12)

• 2021
  • 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
  • 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
  • 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
  • 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
  • 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
  • 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
  • 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
  • 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
  • 2021-03-02 IL IL296069A patent/IL296069A/en unknown
  • 2021-03-02 PY PY202102117301A patent/PY2117301A/es unknown
  • 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
  • 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
  • 2021-03-02 PY PY202102117308A patent/PY2117308A/es unknown
  • 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
  • 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
  • 2021-03-02 TW TW110107293A patent/TWI908772B/zh active
  • 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
  • 2021-03-02 US US17/908,533 patent/US20230159594A1/en active Pending
  • 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
  • 2021-03-02 UY UY0001039109A patent/UY39109A/es unknown
  • 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
  • 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
  • 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
  • 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
  • 2021-03-02 IL IL296068A patent/IL296068A/en unknown
  • 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
  • 2021-03-02 UY UY0001039110A patent/UY39110A/es unknown
  • 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
  • 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
  • 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
• 2022
  • 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
  • 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
  • 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
  • 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown

Patent Citations (5)

Non-Patent Citations (18)

Also Published As

Similar Documents

Legal Events